Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive randomized placebo-controlled study of oral FT-4202 in sickle cell disease
2020-003884-25Phase 2Active
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing FT-4202 with Placebo (2 arms). Primary endpoint: Hemoglobin response rate at Week 24. Started Jan 2021; status: active.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2020-003884-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003884-25.